Skip to main content
Erschienen in: Reactions Weekly 1/2014

01.12.2014 | Case report

Cetuximab/irinotecan

Skin rash: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (FDA MedWatch definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * requires intervention to prevent permanent impairment or damage
Literatur
Zurück zum Zitat Chen Y, et al. Biweekly cetuximab plus FOLFIRI/irinotecan as first/second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer: A retrospective analysis in Southwest Chinese population. Medical Oncology 31: No. 5, Mar 2014 - China Chen Y, et al. Biweekly cetuximab plus FOLFIRI/irinotecan as first/second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer: A retrospective analysis in Southwest Chinese population. Medical Oncology 31: No. 5, Mar 2014 - China
Metadaten
Titel
Cetuximab/irinotecan
Skin rash: case report
Publikationsdatum
01.12.2014
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2014
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-014-5880-5

Weitere Artikel der Ausgabe 1/2014

Reactions Weekly 1/2014 Zur Ausgabe

Case report

Azithromycin

Case report

Azathioprine

Case report

Sorafenib